Securities Law and Shareholder Derivative Cases

Our firm has a successful history of representing clients against people or companies engaged in insider selling or violation of federal securities laws, including cases involving bad faith actions by boards of directors and corporate officers.

Our cases have included:

  • Breach of fiduciary duty
  • Excessive margins
  • Failure of brokerages to supervise brokers
  • Failure to conduct due diligence
  • Failure to disclose material facts and investment risks
  • Failure to diversify
  • False reverse-merger investments
  • Hedge fund fraud
  • High-pressure sales tactics
  • Junk bond funds
  • Recommendation of unsuitable investments
  • Securities fraud
  • Stock churning
  • Structured finance or products
  • Unauthorized trades

These cases include In re: King Pharmaceuticals Inc. Derivative Litigation, in which our firm served as lead counsel in a shareholder derivative action against the board of directors and certain officers of the company, In re Caremark RX, Inc. Stock Option Litigation, in which we served as co-lead counsel in litigation against the board of directors, lead counsel in In re Omnivision Technologies, Inc. Securities Litigation, in which we served as lead counsel and helped obtain a $12.5 million settlement.